Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.67 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.67 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.67 |
| ▸ | IGF2R | P11717 | 6/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18685537 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL18685539 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL12662772 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL12908194 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL18680143 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL13242187 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL21067922 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL21067309 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL22445738 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 | |
| SCHEMBL18680145 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RGJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026085618-A1 | METHOD OF IMMOBILIZING CAPTURE PROBES TO SOLID PHASES FOR TARGET SUBSTANCE DETECTION | YYZ PHARMATECH INC. (CA) | 2026-04-30 | — | — | WO | claimed |
| US-12404479-B2 | Laundry detergent composition containing graft copolymer and benefit agent | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | claimed |
| EP-4555060-A1 | LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT | The Procter & Gamble Company (US) | 2025-05-21 | — | — | EP | claimed |
| US-12181480-B2 | Polyspecificity reagents, methods for their preparation and use | ADIMAB, LLC (US) | 2024-12-31 | — | — | US | claimed |
| WO-2024011345-A1 | LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT | THE PROCTER & GAMBLE COMPANY (US) | 2024-01-18 | — | — | WO | claimed |
| US-20240011108-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ PHARMATECH INC. (CA) | 2024-01-11 | — | — | US | claimed |
| US-20240010954-A1 | LAUNDRY DETERGENT COMPOSITION CONTAINING GRAFT COPOLYMER AND BENEFIT AGENT | THE PROCTER & GAMBLE COMPANY | 2024-01-11 | — | — | US | claimed |
| EP-4232598-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ Pharmatech Inc. (CA) | 2023-08-30 | — | — | EP | claimed |
| CN-116391047-A | Mass spectrometry-based methods and kits for nucleic acid detection and disease diagnosis | YYZ医药科技有限公司 | 2023-07-04 | — | — | CN | claimed |
| WO-2022087730-A1 | MASS SPECTROMETRY-BASED METHODS AND KITS FOR NUCLEIC ACID DETECTION AND DISEASE DIAGNOSTIC | YYZ PHARMATECH INC. (CA) | 2022-05-05 | — | — | WO | claimed |
| EP-2430140-A2 | PERFUME SYSTEMS | The Procter & Gamble Company (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132531-A2 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2010-11-18 | — | — | WO | claimed |
| US-20100287710-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-11-18 | — | — | US | claimed |
| EP-4419916-B1 | TEST SYSTEM FOR OBTAINING A BLOOD COUNT SUITABLE FOR HOME USE AND TELEMEDICINE | IMMUNDIAGNOSTIK AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-12589387-B2 | Integrated fluidic devices and related methods | HELIXBIND, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12578307-B2 | De-clustering ion guide | MICROMASS UK LIMITED (GB) | 2026-03-17 | — | — | US | disclosed |
| US-20160256365-A1 | Hair Conditioning Compositions With Microcapsules | THE PROCTER & GAMBLE COMPANY | 2016-09-08 | — | — | US | disclosed |
| US-20160256364-A1 | Hair Conditioning Compositions With Microcapsules | THE PROCTER & GAMBLE COMPANY | 2016-09-08 | — | — | US | disclosed |
| US-20120258150-A1 | PARTICLES COMPRISING VOLATILE MATERIALS AND PARTICLE GAS SATURATED SOLUTION PROCESSES FOR MAKING SAME | THE PROCTER & GAMBLE COMPANY | 2012-10-11 | — | — | US | disclosed |
| US-20100287710-A1 | PERFUME SYSTEMS | THE PROCTER & GAMBLE COMPANY | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12578307-B2 | De-clustering ion guide | RAN, DDX42, RASSF5 | LGALS3 853/4885LGALS8 928/4885LGALS4 628/4885 |
| US-20160256364-A1 | Hair Conditioning Compositions With Microcapsules | SLC25A20, IL5, PLIN5 | LGALS3 4155/4885LGALS8 3663/4885LGALS4 4138/4885 |
| US-12589387-B2 | Integrated fluidic devices and related methods | CD47, EXOSC4, DIS3 | LGALS3 427/4885LGALS8 241/4885LGALS4 401/4885 |
| US-20160256365-A1 | Hair Conditioning Compositions With Microcapsules | SLC25A20, IL5, PLIN5 | LGALS3 4155/4885LGALS8 3663/4885LGALS4 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.